News

Pharmaceutical News

Pharmaceutical News

ACIP: Vaccine for Meningococcal Disease Okay for High-Risk Infants

  • Date: 06-23-2011 --
  • MedPage Today (06/23/11) Neale, Todd
  • body: The CDC's Advisory Committee on Immunization Practices (ACIP) has recommended the quadrivalent meningococcal vaccine for children as young as 9 months old who are at risk for meningococcal disease. The adopted recommendation targets children with complement component deficiencies, infants who are in a defined risk group for a community or institutional outbreak, and infants traveling to areas where meningococcal disease is epidemic or highly epidemic. Infants would receive one dose at 9 months and a second at 12 months. The CDC director must approve the recommendation and the agency's Morbidity and Mortality Weekly Report must publish it before the policy can become official. In April, the FDA approved Sanofi Pasteur's quadrivalent meningococcal vaccine, Menactra, for use in children as young as 9 months. Menactra has already been approved for individuals ages 2 to 55.
  • URL: http://www.medpagetoday.com/MeetingCoverage/ACIP/27228